arrow
S

Saul N. Faust

university hospital southampton nhs foundation trust
H指数:74
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nasal mucosal humoral responses to SARS-CoV-2 vaccination priming schedules in the UK: a substudy of the Com-COV single-blind, randomised, non-inferiority trial

英国SARS-CoV-2疫苗接种基础免疫程序对鼻黏膜体液反应的影响:Com-COV单盲、随机、非劣效性试验的亚组研究

2026-11-120
OA
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6–17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial

BPZE1(一种鼻内接种的减毒百日咳活疫苗)的免疫原性和安全性评估:在6至17岁健康儿童中与减少破伤风成分的白喉-无细胞百日咳疫苗进行活性对照和安慰剂对照的随机Ⅱb期试验

2026-10-010
OAAI
The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults

COVID-19预免疫和加强平台试验(PICOBOO):在免疫功能健全成人中接种九种获批COVID-19疫苗的疫苗接种反应性

Vaccine
IF3.5
2026-09-010
PRE
The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults

COVID-19预免疫和加强平台试验(PICOBOO):在免疫健全成人中作为第五剂或后续加强剂接种的七种获批COVID-19疫苗的免疫原性、反应原性和安全性

Vaccine
IF3.5
2026-07-010
PRE
A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine

I期、无针头、剂量递增临床试验:pEVAC-PS,一种候选泛Sarbecovirus疫苗

2026-05-180
OAAI
Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study

安全性、定植动力学、传染性和保护性免疫相关性在接种了Bordetella pertussis的英国健康成年人中的研究:一项单中心、开放标签、1期、受控人体感染研究

2026-03-230
OAAI
Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026

《2026年儿童脓毒症和脓毒性休克管理国际指南:生存脓毒症运动》

2026-03-230
PRE
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis

活 attenuated 鼻内百日咳疫苗 BPZE1 在英国的有效性、免疫原性和安全性:一项采用毒力性 Bordetella pertussis 的受控人体感染模型进行的随机、安慰剂对照、2b 期试验

2025-12-010
OAAI
Changes in carriage and serotype diversity of Streptococcus pneumoniae and other respiratory pathobionts in the UK between pre-PCV13 (2006-10), early-PCV13 (2010-12) and late-PCV13 (2012-23) periods

英国Streptococcus pneumoniae及其他呼吸道共生致病菌的携带率和血清型多样性变化,比较了PCV13接种前的时期(2006-2010年)、PCV13早期接种时期(2010-2012年)和PCV13晚期接种时期(2012-2023年)。

2025-09-180
OAAI
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)

ChAdOx1 nCoV-19(AZD1222)疫苗在6-17岁儿童中的安全性与免疫原性:一项2期、单盲、随机对照试验(COV006)的最终结果

Vaccine
IF3.5
2025-08-250
OAAI
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial

蛋白为基础的初次免疫(NVX-CoV2373)与mRNA加强免疫(BNT162b2)的异源COVID-19疫苗接种方案可诱导强烈的体液免疫反应:COV-BOOST试验结果

2025-08-070
OAAI
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial

下一代mRNA-1283 COVID-19疫苗与mRNA-1273疫苗(NextCOVE)的疗效、免疫原性和安全性比较:一项III期、随机、观察者盲法、活性对照试验的结果

2025-07-070
PRE
Requirements and special considerations for drug trials with children across six jurisdictions: 1. Clinical trial application review in the regulatory approval process

儿童药物试验在六个司法管辖区的需求和特殊考虑:1. 监管审批流程中的临床试验申请审查

2025-04-150
OA
Requirements and special considerations for drug trials with children across six jurisdictions: 2. Ethics review in the regulatory approval process

六个司法管辖区儿童药物试验的要求和特殊考虑: 2。监管审批过程中的伦理审查

2025-02-110
OAAI
The Platform Trial I n CO VID-19 Priming and BOO sting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old

VID-19启动和BOO sting (PICOBOO) 的平台试验: 在AZD1222启动的50-<70岁的个体中作为第二次加强剂 (第四剂) 施用的不同新型冠状病毒肺炎疫苗的免疫原性,反应原性和安全性

2024-12-011
OAAI
Outcomes of X-Linked Agammaglobulinaemia Patients

X连锁无丙种球蛋白血症患者的预后情况

2024-11-140
PRE
Non-pharmaceutical interventions for COVID-19 transiently reduced pneumococcal and Haemophilus influenzae carriage in a cross-sectional pediatric cohort in Southampton, UK

在英国南安普敦的横断面儿科队列中,对新型冠状病毒肺炎的非药物干预措施暂时减少了肺炎球菌和流感嗜血杆菌的携带

2024-08-061
OAAI
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial

1个月以上开始口服缬更昔洛韦治疗先天性巨细胞病毒感染引起的感音神经性听力损失: 一项随机临床试验

2024-05-018
OAAI